Kidney transplant · IV immunotherapy
NULOJIX®Belatacept infusions
Patient education and outpatient infusion visits coordinated with your transplant center—serving Beachwood, Cleveland, and Northeast Ohio.
How to use this page
This is general patient education, not a substitute for your transplant physician, pharmacist, or the official Medication Guide and prescribing information. NULOJIX® is a registered trademark of Bristol Myers Squibb.
FDA boxed warning (summary)
Only use NULOJIX as directed by your transplant team. The label carries boxed warnings for increased risks of post-transplant lymphoproliferative disorder (PTLD), progressive multifocal leukoencephalopathy (PML), other malignancies, and serious infections. NULOJIX is contraindicated if you are EBV seronegative or EBV status is unknown. Use in liver transplant is not recommended. Read the full warnings in the prescribing information (PDF) or FDA labeling.
What Is Belatacept?
Belatacept (brand name NULOJIX®) is a protein biologic that blocks a specific immune “second signal” needed for full T-cell activation. It binds CD80/CD86 on antigen-presenting cells so they cannot engage CD28 on T cells as efficiently. That helps reduce the alloimmune response that causes kidney rejection. This mechanism differs from calcineurin inhibitors (for example, tacrolimus or cyclosporine), which act inside T cells and are associated with kidney and metabolic side effects that transplant teams sometimes try to limit.
FDA-Approved Use
NULOJIX is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids, in patients who are EBV seropositive. Always follow the regimen your transplant center prescribes.
Official resources: NULOJIX prescribing information (BMS PDF), HCP clinical overview (BMS), NULOJIX patient site.
Clinical Trial Evidence & Outcomes
FDA approval of NULOJIX was supported by large Phase 3 programs in adults receiving a de novo kidney transplant, comparing belatacept-based maintenance regimens with a cyclosporine-based control regimen (alongside basiliximab induction, MMF, and corticosteroids in the studied protocols). The two pivotal trials are commonly referred to as BENEFIT (standard-criteria donor kidneys) and BENEFIT-EXT (extended-criteria donor kidneys).
| Study | Patient population | What was compared | Themes reported in peer-reviewed summaries |
|---|---|---|---|
| BENEFIT ClinicalTrials.gov NCT00256750 |
Recipients of kidneys from living or standard-criteria deceased donors | Belatacept (more- vs less-intensive schedules studied) vs cyclosporine, each with MMF and steroids after basiliximab induction | Published analyses emphasize differences in renal function measures (such as eGFR) favoring belatacept over time; discussions also address acute rejection in the first year and long-term graft and patient outcomes. |
| BENEFIT-EXT ClinicalTrials.gov NCT00700259 |
Recipients of kidneys from extended-criteria deceased donors | Belatacept vs cyclosporine with the same backbone immunosuppression pattern studied in the program | Similar overarching themes: nephroprotection arguments tied to avoiding chronic CNI exposure while maintaining immunosuppressive efficacy; outcomes interpreted in a higher baseline-risk donor population. |
How to interpret this: Trial results are population averages—they help regulators and transplant physicians weigh benefits and risks, but your outcome depends on donor/recipient factors, adherence, infections, and many variables. Published long-term kidney transplant analyses include Vincenti and colleagues in the New England Journal of Medicine (NEJM 2016). Additional trial summaries appear on BMS clinical resources and in the highlights section of the prescribing information.
Benefit vs. trade-offs
Across published discussions of BENEFIT/BENEFIT-EXT, experts often highlight better preservation of kidney function markers with belatacept versus cyclosporine together with a favorable cardiovascular/metabolic profile in trial cohorts, while noting that early biopsy-proven acute rejection was more frequent with belatacept in some trial arms—emphasizing close surveillance after transplant. Your team explains how this evidence applies to you.
Side Effects & Important Warnings
All immunosuppressants balance rejection prevention against infection and cancer risk. The lists below are educational summaries only. Exact wording, frequencies, and management steps appear in the FDA-approved prescribing information and the Medication Guide you receive from your pharmacy or infusion team.
Boxed warnings & serious risks
- Post-transplant lymphoproliferative disorder (PTLD), including central nervous system involvement, and other malignancies.
- Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection.
- Serious infections (bacterial, viral, fungal, or opportunistic)—immunosuppression reduces your ability to fight infection.
- EBV: NULOJIX is contraindicated if you are EBV-seronegative or EBV status is unknown.
- Liver transplantation: labeling states use is not recommended because of reported excess graft loss and death in studied liver recipients.
Other precautions (examples)
- Live vaccines are generally avoided during potent immunosuppression—follow your transplant team’s vaccine plan.
- Tuberculosis and other endemic infections may need screening or treatment before or during therapy.
- Pregnancy & breastfeeding: discuss risks with your team; manufacturer pregnancy registry information is referenced in labeling.
- Infusion reactions (e.g., hypersensitivity) have been reported—alert staff to symptoms during or after the infusion.
- Routine labs and clinic visits monitor kidney function, blood counts, and infections as directed by your transplant center.
Common adverse reactions (trial experience)
In kidney transplant studies, multiple adverse reactions occurred more often than with placebo or were commonly reported with belatacept-containing regimens. Examples your team may discuss include:
- Blood and lymphatic: anemia, leukopenia, neutropenia
- Gastrointestinal: diarrhea, constipation, nausea, vomiting
- Infections: urinary tract infection, upper respiratory infection, cytomegalovirus (CMV)
- General / vascular: peripheral edema, fever, cough, high blood pressure, headache
- Metabolic: electrolyte changes (such as potassium or phosphate shifts—labs help detect these)
Not everyone experiences these effects; some symptoms may be mild or temporary. Do not stop or change NULOJIX without your transplant clinician.
When to contact your transplant team urgently
Seek immediate guidance for fever ≥100.4°F (38°C), severe or worsening shortness of breath, confusion, new weakness or numbness (especially on one side), trouble speaking, vision changes, severe rash, reduced urine output, or signs of a serious allergic reaction during or after infusion. For emergencies, call 911 or go to the nearest emergency department.
Common questions about NULOJIX
What is belatacept (NULOJIX) used for?
It is used after kidney transplantation to lower the chance of organ rejection, together with other transplant medicines your team selects (commonly basiliximab for induction, MMF, and steroids in the studied regimens).
It is approved only for adults who test positive for prior EBV exposure (EBV seropositive).
Why might someone switch from tacrolimus (or another CNI) to belatacept?
Transplant specialists sometimes prefer a belatacept-based regimen to avoid long-term calcineurin inhibitor toxicity (for example effects on kidney function, blood pressure, lipids, or glucose) in appropriately selected recipients.
Important: switching a stable patient from a CNI is not automatic and may not be suitable for everyone; it requires transplant-center judgment and close monitoring for rejection and infections.
How effective is belatacept? What do the trials show?
Efficacy is evaluated in large transplant trials (notably the BENEFIT and BENEFIT-EXT programs) versus cyclosporine-based control arms. Published long-term analyses describe kidney function and clinical outcomes in those study populations.
For specifics, review peer-reviewed summaries such as Vincenti et al. in the New England Journal of Medicine (NEJM 2016) and your team’s explanation of how trial evidence applies to your situation.
What is the boxed warning for NULOJIX?
The label emphasizes risks of PTLD, PML, other cancers, and serious infections due to immunosuppression. NULOJIX must not be given to patients who are EBV-negative or have unknown EBV status.
Report new neurologic symptoms (confusion, weakness, vision changes), persistent fever, night sweats, or unexplained weight loss promptly to your transplant team.
Who should not receive NULOJIX?
It is contraindicated in transplant recipients who are EBV seronegative or whose EBV status is unknown. Liver transplant recipients are a separate safety consideration; product labeling states use in liver transplantation is not recommended.
Other exclusions and precautions (active serious infections, malignancy history, live vaccines, pregnancy planning) are individualized—your transplant team will review these with you.
How is NULOJIX given?
NULOJIX is an intravenous infusion, typically over about 30 minutes, on a schedule that includes more frequent doses early after transplant and then maintenance infusions every four weeks (exact dates and doses are weight-based per label).
Preparation and administration must follow the manufacturer’s directions (including compatible infusion supplies). Your infusion nurses and transplant pharmacy team handle those details.
What side effects are common?
The prescribing information lists adverse reactions observed in trials—examples often discussed include anemia, diarrhea, constipation, UTI, swelling, cough, fever, and blood pressure changes. Frequencies and severity vary by person.
Use the official label or MedGuide for the complete list and call your transplant coordinator about any symptom that worries you.
Infusions at CarePoint
CarePoint Infusion Center can administer NULOJIX when your transplant program sends an order and infusion plan. We provide nursing monitoring during the visit and coordinate scheduling; medication decisions, labs, infection prophylaxis, and rejection surveillance remain with your transplant team.
For benefit and authorization questions, you may also review our prior authorization page.
Selected references
- Bristol Myers Squibb. NULOJIX (belatacept) Prescribing Information. packageinserts.bms.com (PDF)
- U.S. FDA. Drugs@FDA entry for NULOJIX (search). accessdata.fda.gov
- Vincenti F, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016. NEJM
- Pestana JM, et al. Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys (BENEFIT-EXT). Am J Transplant. 2016;16(11):3192–3201. PMC5516151
Serving Northeast Ohio Communities
CarePoint Infusion Center is your trusted provider for infusion therapy throughout Northeast Ohio. As leading providers in the region, we're conveniently located to serve patients from Cleveland and Beachwood to communities throughout Cuyahoga County. Whether you're searching for "infusion therapy near me" in Cleveland, "IV treatment Beachwood OH", or specialized infusion services anywhere in Northeast Ohio, we're here to help.
We conveniently serve patients from:
And throughout Cuyahoga County and Northeast Ohio. Contact us today to schedule your infusion therapy appointment in Beachwood or Cleveland, Ohio.